1 Flcisch H, Graham R, Russell G, et al .Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo.Science,1969,165:1262. 2 Boonekamp PM, Lowik CWGM, van der Wee-Pals LJA, et al，Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorting cells after dimethylation of the amino group. Bone Miner, 1986,2:29. 3 Burger EH, van der Meer JWM, van de Gevel JS, et al .In vitro formation of osteoclasts from long term cultures of bone marrow mononuclear phagocytes. J Exp Med, 1982, 156:1604. 4 Papapoulos SE, Hoekman K, Lowik CWGM, et al.Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate. J BoneMfiner Res,1989,4;775. 5 国外药讯编辑部.有关Merck公司alendronate的新资料.国外药讯，1993,(7):16. 6 Hodsman AB. Effects of cyclical therapy for osteoporosis using an oral regimen of inorganic phosphate and sodium etidronate: a clinical and bone histomorphometric study.Bone Miner,1989,5:201. 7 Storm T, Thamsborg G, Steiniche T, et al .Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N EnglJ Med,1990,322:1265. 8 Watts NB, Harris ST, tenant HG, et al .Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N EnglJ Med,1990,323:73. 9 Papapoulos SE, Bijvoet OLM, Valkema R, et al .New bisphosphonates in the treatment of osteoporosis. In: Christiansen C, Overgaard K, eds. Osteoporosis 1990. Copenhagen;Osteopress Aps,1990: 1294一1300. 10 Ferreti JL, Cointry G, Capozza R, et al .Biomechanical effects of the full range of useful doses of pamidronate on femur diaphyses and cortical bone tissue in rats. Bone Miner,1990,11:111. 11 Lombardi A, Santora AC, Reid I, et al .Effects ofalendronate on bone mass in women with postmenopausal osteoporosis. Proceedings of Second International Symposium on Osteoporosis. Beijing: 1995:56.12 Karpf DB, Seeman E, Wasnich RD, et al .Three-year treatment with alendronate prevents osteoporotic fractures in women with postmenopausal osteoporosis. Proceedings of Second International Symposium on Osteoporosis. Beijing:1995:56. 13 Kimmel PB, Recker RR, Arlot M, et al.Bone histomorphometry after long-term alendronate treatment for osteoporosis in postmenopausal women. Proceedings of Second International Symposium on Osteoporosis. Beijing:1995:56. 14 Motoie H, Nakamura T, Ouchi N, et al .Effects of the bisphosphonate YM175 on bone mineral density, strength, structure, and turnover in ovariectomized beagles on concomitant dietary calcium restriction. J Bone Miner Res,1995, 10(6):910. 15 Fukumoto S, Matsumoto T, Takebe K, et al .Treatment of malignancy-associated hypercalcemia with YM175, a new bisphosphonate: elevated threshold for parathyroid hormone secretion in hypercalcemic patients. J Clin Endocrinol Metab ,1994,79(1):165. 16 Wuster C, Schoter KH, Thiebaud D, et al.Methylpentylaminopropylidenebisphosphonate(BM21.0955):a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia. Bone Miner, 1993,22(2):77.